Compare Eli Lilly And Co (LLY) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Zscaler Inc — how do they compare? Eli Lilly And Co trades at $1,162 (market cap $1.02T), while Zscaler Inc trades at $149.58 (market cap $24.23B). The key difference: Eli Lilly And Co is far larger — about 42.1× Zscaler Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| LLY | ZS | |
|---|---|---|
Market Cap | $1.02T | $24.23B |
Sector | Health | Technology |
52-Week High | $1.24K | $336.27 |
52-Week Low | $625.65 | $118.05 |
Enterprise Value | $1.06T | $22.55B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Zscaler (ZS) trades at $150.70, up 0.54% with a bullish technical outlook. The stock shows strong revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings consistently beat expectations, and analyst consensus is strongly bullish with a $192.46 price target. However, the company faces class action investigations and rising AI infrastructure costs that pressure margins.
ZS presents a growth opportunity in cybersecurity with Zero Trust adoption and AI security traction, but investors must weigh persistent losses against high valuation multiples. The stock's 34% YTD decline creates potential upside if execution improves, though competitive pressures and profitability concerns remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
